Table 1. Gender and age of cases and controls from each stage of GWAS.
| Status | n (%) | Male (%) | Age<31 years | Age 30–45 years | Age 46–60 years | Age>60 years |
|---|---|---|---|---|---|---|
| 23andMe (Stage 1, n=287,137) | ||||||
| Cases | 6,579 (2.3) | 3,510 (53) | 12 (0.18) | 199 (3) | 1,263 (19) | 5,105 (78) |
| Controls | 280,558 (97.7) | 151,588 (54) | 39,838 (14) | 83,780 (30) | 76,833 (27) | 80,107 (28) |
| Harvard (Stage 2, n=12,343) | ||||||
| Affy | ||||||
| Cases | 367 (6.3) | 183 (49.9) | 0 (0.0) | 91 (24.8) | 213 (58.0) | 63 (17.2) |
| Controls | 5,453 (93.7) | 2,412 (44.2) | 0 (0.0) | 1,952 (36.8) | 2,729 (50.0) | 772 (14.2) |
| Illumina | ||||||
| Cases | 220 (7.0) | 91 (41.4) | 0 (0.0) | 61 (27.7) | 125 (56.8) | 34 (15.5) |
| Controls | 2,901 (93.0) | 232 (8.0) | 0 (0.0) | 1,366 (47.1) | 1,434 (49.4) | 101 (3.5) |
| Omni | ||||||
| Cases | 238 (7.0) | 102 (42.9) | 0 (0.0) | 72 (30.2) | 137 (57.6) | 29 (12.2) |
| Controls | 3,164 (93.0) | 803 (25.4) | 0 (0.0) | 1,401 (44.3) | 1,488 (47.0) | 275 (8.7) |
| All, Stage 2 | ||||||
| Cases | 825 (6.7) | 376 (45.6) | 0 (0.0) | 224 (27.1) | 475 (57.6) | 126 (15.3) |
| Controls | 11518 (93.3) | 3447 (29.9) | 0 (0.0) | 4719 (41.0) | 5651 (49.1) | 1148 (9.9) |
| Combined meta-analysis (n=29,9480) | ||||||
| Cases | 7,404 (2.5) | 3,886 (52) | 12 (0.16) | 423 (5.7) | 1,738 (23) | 5,231 (71) |
| Controls | 29,2076 (97.5) | 155,035 (53) | 39,838 (14) | 88,499 (30) | 82,484 (28) | 81,255 (28) |
GWAS, genome-wide association study.
Counts and percentages for cases and controls (n (%)) are listed above, stratified by stage of GWAS. We also report number and percentage of male subjects, subjects with age <31 years, subjects with age 31–45 years, subjects with age 46–60 years and subjects with age >60 years. Stage 2 cases and controls are further subdivided based on platform used for genotyping.